The oncogene RAS is linked to 30 percent of human cancers, but the search for a targeted therapy for RAS has remained elusive. Three leading RAS researchers from the University of North Carolina Lineberger Comprehensive Cancer Center are playing leading roles at a conference aimed at discussing recent advances that may lead to new advances in targeting the oncogene.
Clinical trials that show positive patient response to systemic therapies for cancer should not necessarily lead to reduction in the use of local therapies such as radiation and surgery.
The Lung Cancer Initiative of North Carolina (LCINC), the state’s leading non-profit organization supporting lung cancer research and education, is proud to welcome Dr. Jared Weiss, medical oncologist with UNC Lineberger Comprehensive Cancer Center’s Thoracic Oncology Program, to serve on the board of directors.
UNC Lineberger member Russell Harris, MD, MPH, Professor of Medicine in the UNC School of Medicine and Adjunct Professor of Epidemiology in the UNC Gillings Global School of Public Health, was quoted in two articles in the New York Times about a major study of the efficacy of breast cancer screening published by BMJ (formerly British Medical Journal).
A comprehensive genetic analysis of invasive bladder cancer tumors has found that the disease shares genetic similarities with two forms of breast cancer, according to researchers at the University of North Carolina Lineberger Cancer Center. Bladder cancer, which is the fourth most common malignancy in men and ninth most common in women in the United States, claimed more than 15,000 patients last year.
“This is an important finding because of the field’s increased interest in ‘metabolic reprogramming’ of immune cells. Understanding how macrophage substrate metabolism impacts inflammation is crucial to our being able to develop novel therapies for obesity and diabetes, and even cancer," said study author Liza Makowski, PhD, assistant professor of nutrition at the Gillings School and member of the UNC Lineberger Comprehensive Cancer Center.
UNC Lineberger receives jointly awarded $1 million research grant to investigate novel target in melanoma
The $1 million award from the Melanoma Research Alliance and the Saban Family Foundation will support research to improve the treatment of melanoma, the most aggressive type of skin cancer.
A team led by Cyrus Vaziri, PhD, and William Janzen at the University of North Carolina at Chapel Hill has received a grant from the National Institutes of Health for research that could help make chemotherapy drugs more effective.
The response of a patient with metastatic brain tumors to treatment with stereotactic radiosurgery in the first six-to-twelve weeks can indicate whether follow-up treatments and monitoring are necessary, according to research conducted at the University of North Carolina.
The UNC Lineberger Comprehensive Cancer Center announces The Marci Kramish Campbell Dissertation Award, a competitive $5,000 award to recognize excellence in dissertation research focused on cancer and the population sciences. This cash award goes directly to the recipient and can be used for any purpose.